Evaluation of Interferon Therapy on Malignant Gliomas

A phase II, multicenter study was conducted by 34 institutions to evaluate the effectiveness of human fibroblast interferon (IFN) in the treatment of patients with malignant gliomas. The response rates to IFN in glioma patients (evaluable cases, n = 120), were 14.0% for malignant glioma, 24.0% for low-grade astrocytoma, and 19.2% overall. No significant difference was observed between systemic administration and local administration. There were only mild adverse reactions.